key: cord-0779880-gikqd3d1
authors: Hassan, Ahmed O.; Feldmann, Friederike; Zhao, Haiyan; Curiel, David T.; Okumura, Atsushi; Tang-Huau, Tsing-Lee; Case, James Brett; Meade-White, Kimberly; Callison, Julie; Lovaglio, Jamie; Hanley, Patrick W.; Scott, Dana P.; Fremont, Daved H.; Feldmann, Heinz; Diamond, Michael S.
title: A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
date: 2021-01-26
journal: bioRxiv
DOI: 10.1101/2021.01.26.428251
sha: e04ea2f9c608cc8ce40d2623559dd3563a4323f0
doc_id: 779880
cord_uid: gikqd3d1

The deployment of a vaccine that limits transmission and disease likely will be required to end the Coronavirus Disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally-administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S) in the upper and lower respiratory tract of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged one month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induced neutralizing antibodies and T cell responses and limited or prevented infection in the upper and lower respiratory tract after SARS-CoV-2 challenge. As this single intranasal dose vaccine confers protection against SARS-CoV-2 in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first isolated in late 47 2019 from patients with severe respiratory illness in China (Zhou et al., 2020b) . SARS-CoV-2 48 infection results in a clinical syndrome, Coronavirus Disease 2019 that can progress 49 to respiratory failure (Guan et al., 2020) and systemic inflammatory disease (Cheung et al., 2020;  50 Mao et al., 2020; Wichmann et al., 2020) . The elderly, immunocompromised, and those with co-51 morbidities (e.g., obesity, diabetes, and hypertension) are at greatest risk of death from COVID-52 19 (Zhou et al., 2020a) . Virtually all countries and territories have been affected with more than 53 97 million infections and 2 million deaths recorded worldwide (https://covid19.who.int/). The rapid 54 expansion and prolonged nature of the COVID-19 pandemic and its accompanying morbidity, 55 mortality, and destabilizing socioeconomic effects have made the development and deployment 56 of a SARS-CoV-2 vaccine an urgent global health priority.

The spike (S) protein of the SARS-CoV-2 virion engages the cell-surface receptor 58 angiotensin-converting enzyme 2 (ACE2) to promote coronavirus entry into human cells (Letko et 59 al., 2020) . Because the S protein is critical for viral entry, it has been targeted for vaccine 60 development and therapeutic antibody interventions. SARS-CoV-2 S proteins are cleaved to yield 61 S1 and S2 fragments, followed by further processing of S2 to yield a smaller S2' protein (Hoffmann 62 et al., 2020) . The S1 protein includes the receptor binding domain (RBD) and the S2 protein 63 promotes membrane fusion. The prefusion form of the SARS-CoV-2 S protein (Wrapp et al., 64 2020), which displays the RBD in an 'up' position, is recognized by potently neutralizing 65 monoclonal antibodies (Barnes et al., 2020; Cao et al., 2020b; Pinto et al., 2020; Tortorici et al., 66 2020; Zost et al., 2020) or protein inhibitors (Cao et al., 2020a) .

Multiple academic and industry groups are developing vaccine candidates that target the 68 SARS-CoV-2 S protein (Burton and Walker, 2020) using several platforms including DNA plasmid, 69 lipid nanoparticle encapsulated mRNA, inactivated virion, subunit, and viral-vectored vaccines 70 (Graham, 2020) , with most requiring two doses. While several vaccines from different platforms 71 4 are in advanced clinical trials in humans to evaluate safety and efficacy, all lead candidates, 72 including the Pfizer/BioNTech BNT162b2 and Moderna 1273 mRNA vaccines (Baden et al., 2020;  73 Polack et al., 2020) 

Immunogenicity analysis. We immunized 12 adult rhesus macaques (RM, Indian origin), 100 aged 3 to 11 years old, with ChAd-Control or ChAd-SARS-CoV-2 (n = 6 each; 3 females, 3 males).

RM received a single immunization of 10 11 viral particles of the ChAd vectors by the intranasal 102 route without adjuvant at day -28 (Fig 1A) . All animals were pre-screened for the absence of 103 neutralizing antibody responses against the simian AdV vector (Fig S1) as well as against SARS-104 CoV-2. Three weeks after vaccination (day -7), we detected IgG antibodies against the S and 105 RBD proteins by ELISA in all RM immunized with ChAd-SARS-CoV-2 but not ChAd-Control 106 vaccines (Fig 1B-C) . Neutralizing antibody responses were assessed using an infectious SARS-

CoV-2 focus-reduction neutralization test (Case et al., 2020) and were detected in all RMs 108 immunized with ChAd-SARS-CoV-2 (Fig 1D) . T cell responses specific to SARS-CoV-2 S were 109 assessed by an IFN-g ELISPOT assay on PBMCs isolated two weeks after vaccination (day -14).

All RMs immunized with ChAd-SARS-CoV-2 but not ChAd-Control developed T cell responses to 111 SARS-CoV-2 S (Fig 1E) . RM (Chandrashekar et al., 2020; Munster et al., 2020) 120 it was less in animals immunized with ChAd-SARS-CoV-2-S than ChAd-Control vaccine (Fig 2A   121 and Table S1 ). Viral loads in the nasal swabs at days +1, +3, +5, and +7 were measured by 122 quantitative reverse transcription PCR (qRT-PCR) using primers for subgenomic (N gene, 123 sgRNA) or genomic (nsp12) RNA. Whereas most of the RMs immunized with ChAd-Control 7 vaccine showed high levels of viral RNA through day+5 with some animals persisting through day 125 +7, lower levels were observed in RMs immunized with ChAd-SARS-CoV-2 (Fig 2B-E) . At day 126 +1, only one RM vaccinated with ChAd-SARS-CoV-2 showed detectable infectious virus in nasal 127 swabs by a tissue culture infectious dose (TCID 50 ) assay, whereas 4 of 6 RM immunized with 128 ChAd-Control were positive (Fig 2F) . At later time points, infectious virus was not recovered from Table 1) . At day +3, only one (from 138 ChAd-control immunized RM) of the 12 BAL fluid samples collected was positive for infectious 139 virus. Consistent with these results, at days +1 and +3, substantially higher levels (100 and 50-140 fold, respectively) of viral RNA were detected in the BAL fluid of RM immunized with ChAd-control 141 compared to ChAd-SARS-CoV-2 (Fig 3A-B ).

At day +7, all animals were euthanized, and tissues were collected. Viral RNA was 143 detected in the cervical lymph nodes (LN), mediastinal LN, and the lung tissues in the majority of 144 ChAd-Control vaccinated animals. However, in ChAd-SARS-CoV-2-S immunized animals, lower, 145 if any, viral RNA was detected (Fig 3C) . Indeed, the viral RNA levels in the combined lung lobes 146 from all ChAd-SARS-CoV-2-S immunized animals were substantially lower than that measured 147 in ChAd-Control-immunized animals (Fig 3D) . To begin to establish correlates of protection, the 148 viral RNA levels in BAL fluid at day +3 were compared to the serum neutralizing or anti-S IgG 149 titers obtained three weeks after immunization. We observed an inverse correlation between viral 150 8 RNA levels in BAL fluid obtained three days after SARS-CoV-2 challenge and neutralizing 151 antibody titers (Fig 3E) . The neutralizing antibody levels correlated better than anti-S IgG levels 152 (P = 0.029, R 2 = 0.74 versus P = 0.21, R 2 = 0.36, respectively) (Fig 3E-F 

In summary, our studies establish that immunization of primates with ChAd-SARS-CoV- 

RM experiments. Twelve healthy rhesus macaques (Macaca mulatta; Indian origin, 346 between 3 and 11 years of age and 4 -10 kg in weight) were divided randomly into two groups 347 of 6 animals (3 females and 3 males). All macaques were immunized 28 days prior to challenge 348 by the intranasal route with a total dose of 10 11 viral particles of ChAd-Control or ChAd-SARS-

CoV-2-S in a total volume of 1 mL (0.5 mL into each nostril). Challenge was performed with a total dose of 1 x10 6 TCID 50 of SARS-CoV-2 equally split between the two routes in a total volume 351 of 5 mL (4 mL intrabronchial; 1 mL intranasal). Animals were monitored at least twice daily 352 throughout the study using an established scoring sheet (Brining et al., 2010; Munster et al., 353 2020). Examinations were performed on days -28, -27, -25, -21, -14, -7, 0, 1, 3, 5 and 7 354 (euthanasia) and included clinical evaluation, thoracic radiographs, venous blood draw, and 355 swabs. Bronchoalveolar lavage (BAL) was performed on day 1 and 3 as described (Singletary et 356 al., 2008) . The study endpoint was day 7. Following euthanasia, necropsies were performed on 357 all animals, and organs were harvested for virology, immunology and pathology. Gross lung 358 lesions were scored by a board-certified veterinary pathologist blinded to the group assignment. 

Plates were incubated at room temperature for 1 h, washed thrice in PBST, and 100 µL of 1-Step 

Cross-neutralization of SARS-CoV-2 by a human 570 monoclonal SARS-CoV antibody

Safety and Efficacy of the BNT162b2 mRNA 574

Covid-19 Vaccine

Airway delivery of an 577 adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in 578 nonhuman primates

Convalescent plasma anti-SARS-CoV-2 spike protein 582 ectodomain and receptor binding domain IgG correlate with virus neutralization

Modification of a common BAL technique to enhance sample diagnostic value

Ultrapotent human antibodies protect against 591 SARS-CoV-2 challenge via multiple mechanisms

ChAdOx1 nCoV-595 19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent 599 Protection against SARS-CoV-2

Immunization with modified vaccinia virus Ankara-based 603 recombinant vaccine against severe acute respiratory syndrome is associated with enhanced 604 hepatitis in ferrets

Autopsy Findings and Venous

Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

DNA vaccine protection against SARS-CoV-2 in 617 rhesus macaques

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, 621 China: a retrospective cohort study

A pneumonia outbreak associated with a new coronavirus of probable bat 625 origin

Rapid isolation and profiling of a diverse panel of 629 human monoclonal antibodies targeting the SARS-CoV-2 spike protein

CoV-2 Vaccine. N Engl J Med.

Barnes, C.O., Jette, C.A., Abernathy, M.E., Dam, K.A., Esswein, S.R., Gristick, H.B., Malyutin, 473 A.G., Sharaf, N.G., Huey-Tubman, K.E., Lee, Y.E., et al. (2020) . SARS-CoV-2 neutralizing 474 antibody structures inform therapeutic strategies. Nature 588, 682-687.

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., 

Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. 

Muñoz-Fontela, C., Dowling, W.E., Funnell, S.G.P., Gsell, P.S., Riveros-Balta, A.X., Albrecht,